Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.4K
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

22
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
22
Peptic Ulcer01:27

Peptic Ulcer

43
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
43
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

29
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
29
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.9K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.6K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Helicobacter pylori and its Association with Extragastric Diseases in a Tertiary Hospital from East Bavaria.

Journal of gastrointestinal and liver diseases : JGLD·2025
Same author

Liver cirrhosis is a risk-factor for Pneumocystis jirovecii associated mortality.

Frontiers in medicine·2024
Same author

The influence of gastric atrophy on <i>Helicobacter pylori</i> antibiotics resistance in therapy-naïve patients.

Frontiers in microbiology·2022
Same author

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

International journal of cancer·2019
Same author

Accuracy of Different Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis.

Digestion·2019
Same author

Combined Gastric and Colorectal Cancer Screening-A New Strategy.

International journal of molecular sciences·2018

Related Experiment Video

Updated: Apr 23, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

879

Helicobacter pylori.

Peter Malfertheiner1, Michael Selgrad

  • 1Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany.

Current Opinion in Gastroenterology
|October 1, 2014
PubMed
Summary
This summary is machine-generated.

New Helicobacter pylori treatments combat antibiotic resistance, with quadruple therapy showing promise. Early eradication is key for gastric cancer prevention, and H. pylori may also increase extragastric cancer risk.

More Related Videos

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability
09:05

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability

Published on: November 21, 2014

15.1K
Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

867

Related Experiment Videos

Last Updated: Apr 23, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

879
High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability
09:05

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability

Published on: November 21, 2014

15.1K
Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

867

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Oncology

Background:

  • Standard triple therapy for H. pylori eradication is failing due to rising antibiotic resistance.
  • This necessitates exploring alternative treatment strategies and understanding H. pylori's broader health implications.

Purpose of the Study:

  • To review novel H. pylori eradication therapies.
  • To assess H. pylori's role in primary and secondary gastric cancer prevention.
  • To examine H. pylori's association with extragastric malignancies.

Main Methods:

  • Review of current literature on H. pylori treatment efficacy.
  • Analysis of data on gastric cancer prevention strategies.
  • Evaluation of evidence linking H. pylori to extragastric cancers.

Main Results:

  • Quadruple therapies (bismuth-based and nonbismuth-based) are more effective than standard triple therapy, especially against resistant strains.
  • Levofloxacin is a viable second-line option but requires cautious use due to emerging resistance.
  • H. pylori eradication is effective for primary gastric cancer prevention; its role in secondary prevention is unclear.
  • Emerging evidence suggests H. pylori is a risk factor for extragastric cancers.

Conclusions:

  • Treatment regimens for H. pylori should be personalized based on local antibiotic resistance profiles.
  • Early H. pylori eradication offers the most benefit for gastric cancer prevention.
  • H. pylori is increasingly implicated as a risk factor for various extragastric cancers.